Novel orally available salvinorin a analog PR-38 protects against experimental colitis and reduces abdominal pain in mice by interaction with opioid and cannabinoid receptors

Biochemical Pharmacology

Volumn 92, Issue 4, 2014, Pages 618-626

  Sałaga, Maciej ^a   Polepally, Prabhakar Reddy ^b   Zakrzewski, Piotr K ^c   Cygankiewicz, Adam ^c   Sobczak, Marta ^a   Kordek, Radzisław ^a   Zjawiony, Jordan K ^b   Krajewska, Wanda M ^c   Fichna, Jakub ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c UNIVERSITY OF LODZ   (Poland)

Author keywords

Experimental colitis; Inflammatory bowel diseases; Intestinal inflammation; PR 38

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; BINALTORPHIMINE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; MYELOPEROXIDASE; OPIATE RECEPTOR; PR 38; SALVINORIN A; UNCLASSIFIED DRUG; 2-O-CINNAMOYLSALVINORIN B; ANALGESIC AGENT; CLERODANE DERIVATIVE; TRINITROBENZENESULFONIC ACID;

ABDOMINAL PAIN; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; BEHAVIOR; CONTROLLED STUDY; ENZYME ACTIVITY; EXPERIMENTAL COLITIS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; COLITIS; DRUG EFFECTS; ORAL DRUG ADMINISTRATION; TOXICITY;

ABDOMINAL PAIN; ADMINISTRATION, ORAL; ANALGESICS; ANIMALS; COLITIS; DITERPENES, CLERODANE; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, CANNABINOID; RECEPTORS, OPIOID; TRINITROBENZENESULFONIC ACID;

EID: 84912083696     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.09.018     Document Type: Article

References (35)

1. Bodnar RJ. Endogenous opiates and behavior: 2006. Peptides 2007;28:2435-513.
2. Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 2010;126:21-38.
3. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997;74:129-80.
4. Fickel J, Bagnol D, Watson SJ, Akil H. Opioid receptor expression in the rat gastrointestinal tract: a quantitative study with comparison to the brain. Brain Res Mol Brain Res 1997;46:1-8.
5. Pol O, Alameda F, Puig MM. Inflammation enhances mu-opioid receptor transcription and expression in mice intestine. Mol Pharmacol 2001;60:894-9.
6. Sobczak M, Salaga M, Storr MA, Fichna J. Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives. J Gastroenterol 2013.
7. Izzo AA, Fezza F, Capasso R, Bisogno T, Pinto L, Iuvone T, et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 2001;134:563-70.
8. Kimball ES, Schneider CR, Wallace NH, Hornby PJ. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol 2006;291:G364-71.
9. Pol O, Palacio JR, Puig MM. The expression of delta- and kappa-opioid receptor is enhanced during intestinal inflammation in mice. J Pharmacol Exp Ther 2003;306:455-62.
10. Philippe D, Chakass D, Thuru X, Zerbib P, Tsicopoulos A, Geboes K, et al. Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation. Gut 2006;55:815-23.
11. Diop L, Riviere PJ, Pascaud X, Junien JL. Peripheral kappa-opioid receptors mediate the antinociceptive effect of fedotozine (correction of fetodozine) on the duodenal pain reflex inrat. Eur J Pharmacol 1994;271:65-71.
12. Kikuchi A, Ohashi K, Sugie Y, Sugimoto H, Omura H. Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity. J Pharmacol Sci 2008;106:219-24.
13. Stein C, Clark JD, Oh U, Vasko MR, Wilcox GL, Overland AC, et al. Peripheral mechanisms of pain and analgesia. Brain Res Rev 2009;60:90-113.
14. Stein C, Schafer M, Machelska H. Attacking pain at its source: new perspectives on opioids. Nat Med 2003;9:1003-8.
15. Burton MB, Gebhart GF. Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. J Pharmacol Exp Ther 1998;285:707-15.
16. Sanson M, Bueno L, Fioramonti J. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil 2006;18:949-56.
17. Salaga M, Polepally PR, Sobczak M, Grzywacz D, Kamysz W, Sibaev A, et al. Do Rego JC, Zjawiony JK, Fichna J. Novel orally available Savinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. J Pharmacol Exp Ther 2014;350:69-78.
18. Fichna J, Dicay M, Lewellyn K, Janecka A, Zjawiony JK, MacNaughton WK, et al. A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors. Inflamm Bowel Dis 2012;18:1137-45.
19. Cadman E, Bostwick JR, Eichberg J. Determination of protein by a modified Lowry procedure in the presence of some commonly used detergents. Anal Biochem 1979;96:21-3.
20. Stawinska M, Cygankiewicz A, Trzcinski R, Mik M, Dziki A, Krajewska WM. Alterations of Chk1 and Chk2 expression in colon cancer. Int J Colorectal Dis 2008;23:1243-9.
21. Fichna J, Sibaev A, Salaga M, Sobczak M, Storr M. The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice. Neurogastroenterol Motil 2013;25:e550-9.
22. Walker JS. Anti-inflammatory effects of opioids. Adv Exp Med Biol 2003;521:148-60.
23. Smirnov MS, Kiyatkin EA. Behavioral and temperature effects of delta 9-tetrahydrocannabinol in human-relevant doses in rats. Brain Res 2008;1228:145-60.
24. Rawls SM, Benamar K. Effects of opioids, cannabinoids, and vanilloids on body temperature. Front Biosci (Schol Ed) 2011;3:822-45.
25. Ranganathan M, Schnakenberg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA, et al. Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the kappa opioid agonist Salvinorin A in humans. Biol Psychiatry 2012;72:871-9.
26. Williams J, Haller VL, Stevens DL, Welch SP. Decreased basal endogenous opioid levels in diabetic rodents: effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception. Eur J Pharmacol 2008;584:78-86.
27. da Fonseca PD, Klein A, de Castro PA, da Fonseca Pacheco CM, de Francischi JN, Duarte ID. The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors. Br J Pharmacol 2008;154:1143-9.
28. Capasso R, Borrelli F, Cascio MG, Aviello G, Huben K, Zjawiony JK, et al. Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors. Br J Pharmacol 2008;155:681-9.
29. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004;74:1317-24.
30. Rios C, Gomes I, Devi LA. mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 2006;148:387-95.
31. Pickel VM, Chan J, Kash TL, Rodriguez JJ, Mackie K. Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. Neuroscience 2004;127:101-12.
32. Wager-Miller J, Westenbroek R, Mackie K. Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example. Chem Phys Lipids 2002;121:83-9.
33. Milligan G, Bouvier M. Methods to monitor the quaternary structure of G protein-coupled receptors. FEBS J 2005;272:2914-25.
34. Hojo M, Sudo Y, Ando Y, Minami K, Takada M, Matsubara T, et al. mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci 2008;108:308-19.
35. Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, et al. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies. Neuropharmacology 2012;63:905-15.